| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/24/2006 | US6989375 Contacting a target cell with DNA-damaging agent; removing DNA-damaging agent from target cell; transferring transgene into target cell between about 1-3 days after removing DNA-damaging agent |
| 01/24/2006 | US6989374 Gene therapy for cardiomyopathy |
| 01/24/2006 | US6989365 Methods of treatment with erythropoietin and albumin fusion protein |
| 01/24/2006 | US6989270 Using polyamide nucleic acid oligomers to engender a biological response |
| 01/24/2006 | US6989264 Generating adenovirus-associated vector; obtain cells, transform with expression vector, propagate, recover transformed cells, propagate and recover vectors |
| 01/24/2006 | US6989262 Plasmin variants and uses thereof |
| 01/24/2006 | US6989261 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| 01/24/2006 | US6989255 for protection against staphylococcus infection; fusion proteins |
| 01/24/2006 | US6989146 Stress proteins and peptides and methods of use thereof |
| 01/19/2006 | WO2006007372A2 Drug delivery product and methods |
| 01/19/2006 | WO2006006722A1 Method of controlling cell functions |
| 01/19/2006 | WO2005111233A3 Methods and kits to detect hereditary angioedema type iii |
| 01/19/2006 | WO2005089123A3 Therapeutic anti-cancer dna |
| 01/19/2006 | WO2005065268A3 Oligonucleotide compound and method for treating nidovirus infections |
| 01/19/2006 | WO2005062995A3 INHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASES A2β OR A2Ϝ INHIBIT HORMONE-INDUCED DIFFERENTIATION OF 3T3-L1 PREADIPOCYTES |
| 01/19/2006 | WO2005038005A3 Shc proteins as therapeutic targets in proliferative diseases |
| 01/19/2006 | WO2005037317A3 Mast cell-derived renin |
| 01/19/2006 | WO2004065581A3 Transposon-insulator element delivery systems |
| 01/19/2006 | US20060015958 Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
| 01/19/2006 | US20060015954 GPR54 knock-out mammals and screening methods using them |
| 01/19/2006 | US20060015951 Proteins involved in the regulation of energy homeostasis |
| 01/19/2006 | US20060014931 Novel promoter |
| 01/19/2006 | US20060014930 Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 01/19/2006 | US20060014715 Control of gene expression |
| 01/19/2006 | US20060014714 Genetic induction of anti-viral immune response and genetic vaccine for viruses |
| 01/19/2006 | US20060014713 Immunostimulatory oligonucleotide multimers |
| 01/19/2006 | US20060014712 Controlled delivery of therapeutic compounds |
| 01/19/2006 | US20060014711 Methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| 01/19/2006 | US20060014710 Immunization of infants |
| 01/19/2006 | US20060014695 Hpma-polyamine conjugates and uses therefore |
| 01/19/2006 | US20060014688 Methods of inhibiting tumor cell proliferation |
| 01/19/2006 | US20060014686 Screening for agents that modulate the activity or expression of FOXM1; determining whether a subject has lung, colon, or breast cancer |
| 01/19/2006 | US20060014683 Procoagulant protein comprising polypeptide with amino acid substitutions; resistant to activated protein C; von Willebrand factor binding site deleted and thrombin cleavage site is mutated; treating hemophilia |
| 01/19/2006 | US20060014682 Chemokine receptor antagonist peptide with a sequence homologous to SDF-1 wherein at least one amino acid at positions five to eight are substituted with proline; proliferative agents; self-regeneration of stem cells |
| 01/19/2006 | US20060014679 Drug screening; diabetes, obesity, hyperlipemia, arteriosclerosis, hypertension, cardiovascular disorders |
| 01/19/2006 | US20060014669 Method for treating cancer and increasing hematocrit levels |
| 01/19/2006 | US20060014288 Nerve regeneration |
| 01/19/2006 | US20060014253 Lamprey GnRH-III polypeptides and methods of making thereof |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060014222 Antibodies |
| 01/19/2006 | US20060014204 Methods of inducing formation of functional and organized lymphatic vessels |
| 01/19/2006 | US20060014180 Human phosphatase RET31, and variants thereof |
| 01/19/2006 | US20060014173 PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use |
| 01/19/2006 | US20060014158 Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems |
| 01/19/2006 | US20060013883 Poloxamer and poloxamine compositions for nucleic acid delivery |
| 01/19/2006 | US20060013832 Methods for treating HIV infected subjects |
| 01/19/2006 | US20060013817 identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. |
| 01/19/2006 | US20060013814 Methods for preventing pressure-induced apoptotic neural-cell death |
| 01/19/2006 | US20060013811 Methods of treating IgE-associated disorders and compositions for use therein |
| 01/19/2006 | US20060013805 Transgenic circulating endothelial cells |
| 01/19/2006 | US20060013803 Modified dendritic cells |
| 01/19/2006 | US20060013772 Method and device to recover diagnostic and therapeutic agents |
| 01/19/2006 | CA2573176A1 Nup98-hox fusions for expansion of hemopoietic stem cells |
| 01/19/2006 | CA2570313A1 Drug delivery product and methods |
| 01/18/2006 | EP1617219A1 Element having bioactive substance fixed thereto |
| 01/18/2006 | EP1617216A1 Novel method of screening |
| 01/18/2006 | EP1616961A1 Vectors and methods for gene transfer to cells |
| 01/18/2006 | EP1616960A2 Human pancreatic cell lines: developments and uses |
| 01/18/2006 | EP1616957A1 Vector |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616620A2 Method for coating particles |
| 01/18/2006 | EP1616580A2 Alpha-amylase transcription factor |
| 01/18/2006 | EP1616579A1 CD40 binding molecules and CTL peptides for treating tumors |
| 01/18/2006 | EP1616578A1 Compositions and methods for delivery of genetic material |
| 01/18/2006 | EP1616012A2 Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof |
| 01/18/2006 | EP1616000A1 Expression of proteins in cord blood-derived endothelial cells |
| 01/18/2006 | EP1615943A2 Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2 |
| 01/18/2006 | EP1615670A2 Targets for tumor growth inhibition |
| 01/18/2006 | EP1615665A2 Delivery of immune response modifier compounds |
| 01/18/2006 | EP1615658A1 Inhibition of tumor cell proliferation by foxm1b inhibitors |
| 01/18/2006 | EP1539816B1 Thrombin-cleavable factor x analogues |
| 01/18/2006 | EP1513559A4 Increased delivery of a nucleic acid constrtuct in vivo by the poly-l-glutamate (plg) system |
| 01/18/2006 | EP1169475B1 Diagnosis of a person's risk for developing diabetic retinopathy |
| 01/18/2006 | EP1127068B1 Immunotherapeutic methods using epitopes of wt-1 and gata-1 |
| 01/18/2006 | EP1097162B1 Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages |
| 01/18/2006 | EP0782630B1 Polycystic kidney disease gene |
| 01/18/2006 | CN1723277A Culture medium composition, culture method, and myoblasts obtained, and their uses |
| 01/18/2006 | CN1721530A Process for inhibiting gene expression |
| 01/18/2006 | CN1721444A Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 01/18/2006 | CN1720999A Hab18G/CD147 molecule small segment interfering RNA medicine and application thereof |
| 01/18/2006 | CN1720998A Preparation and application of pig interleukin-2 gene anti-infectious preparation |
| 01/18/2006 | CN1237179C Targeted artificial gene delivery |
| 01/18/2006 | CN1237178C Use and constructing plan of anticancer recombined gland virus with tumour CHK1 as target of medicine |
| 01/18/2006 | CN1237177C Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent |
| 01/17/2006 | US6987006 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |
| 01/17/2006 | US6987005 Where the human SNORF33 receptor has the amino acid sequence SEQ ID NO: 6; encoded by ATCC deposited plasmids; activated by either tyramine, tryptamine, or beta -phenyl-ethylamine; vectors; cells; membranes; nervous system disorders |
| 01/17/2006 | US6987001 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| 01/17/2006 | US6986900 biocompatible implants for delivery of pharmaceutically active agents to the posterior segment of the eye; having a scleral surface, an orbital surface, an injection port on the orbital surface, and a fluid conducting passageway |
| 01/17/2006 | CA2374882C Molecular characterisation of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis |
| 01/12/2006 | WO2006004939A2 Polymorphisms and haplotypes of the alpha 2c adrenergic receptor gene |
| 01/12/2006 | WO2006004173A1 Viral particle-like construct and method of forming the same under physiological conditions |
| 01/12/2006 | WO2006002627A2 Chicken deoxycytidine and deoxyadenosine kinase enzymes and their use |
| 01/12/2006 | WO2005103693A3 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| 01/12/2006 | WO2005097207A3 Rna interference modulators of hedgehog signaling and uses thereof |
| 01/12/2006 | WO2005090573A3 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 01/12/2006 | WO2005033266A3 Regulation of acheron expression |
| 01/12/2006 | WO2005025495A3 Methods and compositions for blocking progression of a disease state |
| 01/12/2006 | WO2004090108A3 Irna conjugates |